IN2014DN08562A - - Google Patents
Info
- Publication number
- IN2014DN08562A IN2014DN08562A IN8562DEN2014A IN2014DN08562A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A IN 8562DEN2014 A IN8562DEN2014 A IN 8562DEN2014A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A
- Authority
- IN
- India
- Prior art keywords
- sert
- prodrugs
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical compositions
- Prior art date
Links
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 abstract 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 abstract 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624291P | 2012-04-14 | 2012-04-14 | |
| US201261624292P | 2012-04-14 | 2012-04-14 | |
| US201261624293P | 2012-04-14 | 2012-04-14 | |
| US201261671723P | 2012-07-14 | 2012-07-14 | |
| US201261671713P | 2012-07-14 | 2012-07-14 | |
| PCT/US2013/036514 WO2013155505A1 (en) | 2012-04-14 | 2013-04-14 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08562A true IN2014DN08562A (forum.php) | 2015-05-22 |
Family
ID=49328233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8562DEN2014 IN2014DN08562A (forum.php) | 2012-04-14 | 2013-04-14 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US9428506B2 (forum.php) |
| EP (4) | EP2836211B1 (forum.php) |
| JP (6) | JP6334511B2 (forum.php) |
| KR (1) | KR20140146192A (forum.php) |
| CN (1) | CN104519886B (forum.php) |
| AU (1) | AU2013245702A1 (forum.php) |
| CA (1) | CA2870303A1 (forum.php) |
| ES (1) | ES2727815T3 (forum.php) |
| IN (1) | IN2014DN08562A (forum.php) |
| MX (1) | MX2014012374A (forum.php) |
| RU (1) | RU2014145682A (forum.php) |
| WO (3) | WO2013155506A1 (forum.php) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626766B (zh) | 2007-03-12 | 2017-06-09 | 细胞内治疗公司 | 与取代的杂环稠合的γ‑咔啉的合成 |
| DK2262505T3 (en) | 2008-03-12 | 2015-01-05 | Intra Cellular Therapies Inc | Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID |
| US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| WO2011133224A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| IN2014DN08562A (forum.php) | 2012-04-14 | 2015-05-22 | Intra Cellular Therapies Inc | |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| PL2968320T3 (pl) | 2013-03-15 | 2021-05-17 | Intra-Cellular Therapies, Inc. | Związki organiczne |
| MX395458B (es) | 2013-12-03 | 2025-03-25 | Intra Cellular Therapies Inc | Metodos novedosos |
| KR20170012209A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| KR20170012210A (ko) * | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| CN104003987B (zh) * | 2014-06-03 | 2016-03-23 | 中国药科大学 | 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| US20170007618A1 (en) * | 2015-06-17 | 2017-01-12 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
| HUE064667T2 (hu) | 2016-01-26 | 2024-04-28 | Intra Cellular Therapies Inc | Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra |
| SI3407889T1 (sl) | 2016-03-25 | 2021-09-30 | Intra-Cellular Therapies, Inc. | Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema |
| EP3436455A4 (en) | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | NOVEL SALTS AND CRYSTALS |
| JP6997718B2 (ja) | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| CN110072518B (zh) * | 2016-10-12 | 2021-10-26 | 细胞内治疗公司 | 无定形固体分散体 |
| JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7458786B2 (ja) * | 2017-02-15 | 2024-04-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善された光療法システムおよび使用方法 |
| US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
| CN110430879B (zh) | 2017-03-24 | 2023-04-21 | 细胞内治疗公司 | 新组合物和方法 |
| CN110636845A (zh) * | 2017-04-10 | 2019-12-31 | 雷迪博士实验室有限公司 | 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体 |
| MX2020000968A (es) | 2017-07-26 | 2020-09-28 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2019023063A1 (en) * | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| JP2020535231A (ja) * | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| EP3765021A4 (en) | 2018-03-16 | 2022-03-09 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
| JP7462568B2 (ja) | 2018-03-23 | 2024-04-05 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| CA3095101A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Deuterated octahydro-quinoxaline derivatives and pharmaceutical compositions thereof use in the treatment of diseases involving serotonin 5-ht2a, dopamine d1/d2 and/or serotonin reuptake transporter (sert) pathways |
| JP7568512B2 (ja) | 2018-05-04 | 2024-10-16 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の塩 |
| BR112020024885A2 (pt) | 2018-06-06 | 2021-03-09 | Intra-Cellular Therapies, Inc. | Novos sais e cristais |
| CA3102948A1 (en) * | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7483671B2 (ja) | 2018-06-11 | 2024-05-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 置換ヘテロ環縮合ガンマ－カルボリン類合成 |
| EP3811371A1 (en) | 2018-06-21 | 2021-04-28 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| EP3843729A4 (en) | 2018-08-29 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW COMPOSITIONS AND METHODS |
| BR112021003838A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| CN112584837A (zh) | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
| US11541002B2 (en) | 2018-09-07 | 2023-01-03 | Aquestive Therapeutics, Inc. | Oral film compositions and dosage forms having precise active dissolution profiles |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CA3121635A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Serotonin 5-ht2a receptor antagonist |
| KR20210104834A (ko) | 2018-12-17 | 2021-08-25 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로사이클 융합 감마-카르볼린 합성 |
| CA3121631A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| US12195463B2 (en) | 2018-12-21 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020132605A1 (en) * | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20210000822A1 (en) | 2019-07-07 | 2021-01-07 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2021062307A1 (en) | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2020373100A1 (en) | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| CN115038451A (zh) | 2019-11-14 | 2022-09-09 | 阿奎斯蒂弗医疗股份有限公司 | 多模式组合物和治疗方法 |
| US11753419B2 (en) | 2019-12-11 | 2023-09-12 | Intra-Cellular Therapies, Inc. | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
| JP2024505429A (ja) | 2021-01-15 | 2024-02-06 | アクエスティブ セラピューティクス インコーポレイテッド | プロドラッグ組成物及び治療の方法 |
| EP4304554A1 (en) | 2021-03-09 | 2024-01-17 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| EP4525874A1 (en) | 2022-05-18 | 2025-03-26 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2024173901A1 (en) | 2023-02-17 | 2024-08-22 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| US20250352469A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices, and methods |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US3606908A (en) | 1969-11-26 | 1971-09-21 | Trico Products Corp | Ventilation system for volatile fluid |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| JPS5014494A (forum.php) * | 1973-06-11 | 1975-02-15 | ||
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| SE8304361D0 (sv) * | 1983-08-10 | 1983-08-10 | Ferrosan Ab | Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS6175A (ja) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体 |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| EP0238059B1 (en) | 1986-03-19 | 1993-06-16 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same |
| DE3786365T2 (de) | 1986-04-07 | 1993-10-21 | Ihara Chemical Ind Co | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-on-Derivate und diese enthaltende Gartenbau- und landwirtschaftliche Fungizidmittel. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| DE10299048I2 (de) | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| SG47445A1 (en) | 1993-11-19 | 1998-04-17 | Janssen Pharmaceutica Nv | Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| ATE229499T1 (de) | 1998-02-26 | 2002-12-15 | Massachusetts Inst Technology | Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| DE69929609T2 (de) | 1998-07-10 | 2006-09-28 | Massachusetts Institute Of Technology, Cambridge | Liganden für metalle und metall-katalysiertes verfahren |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| HUP0104721A3 (en) | 1998-12-17 | 2006-07-28 | Alza Corp Mountain View | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| JP4916633B2 (ja) | 1999-06-15 | 2012-04-18 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | 置換複素環縮合ガンマ−カルボリン |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| SK7042003A3 (en) | 2000-12-20 | 2004-07-07 | Bristol Myers Squibb Co | Substituted pyridoindoles as serotonin agonists and antagonists |
| CA2445159C (en) | 2001-04-24 | 2012-09-11 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| JP2005526691A (ja) | 2001-08-08 | 2005-09-08 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 治療剤１Ｈ−ピリド［４，３−ｂ］インドール |
| HRP20050077B1 (hr) | 2002-07-29 | 2013-11-22 | Alza Corporation | Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| EP1534671A4 (en) | 2002-08-02 | 2007-10-24 | Massachusetts Inst Technology | FORMATION OF CARBON-HETEROATOME AND CARBON-CARBON BONDS CATALYZED WITH COPPER |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| JP4486505B2 (ja) | 2002-12-19 | 2010-06-23 | ブリストル−マイヤーズ スクイブ カンパニー | セロトニン・レセプタ作用薬および拮抗薬としての置換トリ環式ガンマ−カルボリン化合物 |
| CN1816524B (zh) | 2003-01-16 | 2012-06-27 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
| RU2006106429A (ru) | 2003-07-21 | 2006-08-27 | СмитКлайн Бичем Корпорейшн (US) | Соль (2s, 4s)-4-фтор-1-(4-фтор-бета-(4-фторфенил)-l-фенилаланил) -2-пирролидинкарбонитрила с пара-толуолсульфоновой кислоты и ее безводные кристаллические формы |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| EP1756102A1 (en) | 2004-03-05 | 2007-02-28 | Pharma C S.A. | 8-PHENOXY-GammaCARBOLINE DERIVATIVES |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| DK1793671T3 (da) * | 2004-09-20 | 2011-08-22 | Sinai School Medicine | Anvendelse af memantin (namenda) til behandling af autisme, tvangstilstand og impulsivitet |
| WO2006032999A1 (en) * | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
| BRPI0519054A2 (pt) | 2004-12-15 | 2008-12-23 | Hoffmann La Roche | fenil metanonas bi e tricÍclicas substituÍdas como inibidores de transportador i de glicina (glyt-1) para o tratamento de doenÇa de alzheimer |
| CA2611312C (en) * | 2005-06-06 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN103626766B (zh) | 2007-03-12 | 2017-06-09 | 细胞内治疗公司 | 与取代的杂环稠合的γ‑咔啉的合成 |
| MX2010001218A (es) | 2007-08-01 | 2010-04-07 | Medivation Neurology Inc | Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos. |
| EP2262502A4 (en) * | 2008-02-05 | 2011-12-28 | Clera Inc | Compositions and methods for alleviating depression or improving cognition |
| DK2262505T3 (en) | 2008-03-12 | 2015-01-05 | Intra Cellular Therapies Inc | Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID |
| US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| WO2011133224A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IN2014DN08562A (forum.php) | 2012-04-14 | 2015-05-22 | Intra Cellular Therapies Inc | |
| WO2014005194A1 (en) | 2012-07-06 | 2014-01-09 | The University Of Melbourne | Immunological reagents and uses therefor |
| PL2968320T3 (pl) | 2013-03-15 | 2021-05-17 | Intra-Cellular Therapies, Inc. | Związki organiczne |
| US9161061B2 (en) | 2013-03-15 | 2015-10-13 | Pictech Management Limited | Data storage and exchange device for color space encoded images |
| MX395458B (es) | 2013-12-03 | 2025-03-25 | Intra Cellular Therapies Inc | Metodos novedosos |
| KR20170012210A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| KR20170012209A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| HUE064667T2 (hu) | 2016-01-26 | 2024-04-28 | Intra Cellular Therapies Inc | Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra |
| SI3407889T1 (sl) | 2016-03-25 | 2021-09-30 | Intra-Cellular Therapies, Inc. | Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema |
| EP3436455A4 (en) | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | NOVEL SALTS AND CRYSTALS |
| CN110072518B (zh) | 2016-10-12 | 2021-10-26 | 细胞内治疗公司 | 无定形固体分散体 |
| CN110430879B (zh) | 2017-03-24 | 2023-04-21 | 细胞内治疗公司 | 新组合物和方法 |
| WO2019023063A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| MX2020000968A (es) | 2017-07-26 | 2020-09-28 | Intra Cellular Therapies Inc | Compuestos organicos. |
-
2013
- 2013-04-14 IN IN8562DEN2014 patent/IN2014DN08562A/en unknown
- 2013-04-14 WO PCT/US2013/036515 patent/WO2013155506A1/en not_active Ceased
- 2013-04-14 MX MX2014012374A patent/MX2014012374A/es unknown
- 2013-04-14 CN CN201380030774.2A patent/CN104519886B/zh not_active Expired - Fee Related
- 2013-04-14 AU AU2013245702A patent/AU2013245702A1/en not_active Abandoned
- 2013-04-14 EP EP13776189.6A patent/EP2836211B1/en active Active
- 2013-04-14 WO PCT/US2013/036512 patent/WO2013155504A1/en not_active Ceased
- 2013-04-14 WO PCT/US2013/036514 patent/WO2013155505A1/en not_active Ceased
- 2013-04-14 US US14/394,467 patent/US9428506B2/en active Active
- 2013-04-14 CA CA2870303A patent/CA2870303A1/en not_active Abandoned
- 2013-04-14 EP EP20190036.2A patent/EP3791879A1/en active Pending
- 2013-04-14 KR KR1020147031752A patent/KR20140146192A/ko not_active Withdrawn
- 2013-04-14 JP JP2015505971A patent/JP6334511B2/ja active Active
- 2013-04-14 RU RU2014145682A patent/RU2014145682A/ru not_active Application Discontinuation
- 2013-04-14 EP EP13776208.4A patent/EP2836212A4/en not_active Ceased
- 2013-04-14 ES ES13776189T patent/ES2727815T3/es active Active
- 2013-04-14 EP EP13776297.7A patent/EP2836213B1/en active Active
- 2013-04-14 US US14/394,470 patent/US20150080404A1/en not_active Abandoned
- 2013-04-14 JP JP2015505972A patent/JP6242855B2/ja active Active
- 2013-04-14 JP JP2015505973A patent/JP2015514135A/ja not_active Withdrawn
- 2013-04-14 US US14/394,469 patent/US11053245B2/en active Active
-
2018
- 2018-06-05 JP JP2018107717A patent/JP2018168161A/ja not_active Withdrawn
-
2019
- 2019-09-27 US US16/585,251 patent/US11124514B2/en active Active
-
2020
- 2020-07-10 US US16/926,552 patent/US20210002280A1/en active Pending
- 2020-07-10 US US16/926,551 patent/US20200407362A1/en active Pending
-
2021
- 2021-03-08 JP JP2021035948A patent/JP2021098724A/ja active Pending
- 2021-08-18 US US17/405,736 patent/US11958852B2/en active Active
-
2023
- 2023-08-24 JP JP2023136052A patent/JP2023159345A/ja active Pending
-
2024
- 2024-03-11 US US18/601,923 patent/US20240208974A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08562A (forum.php) | ||
| MX2012012277A (es) | Compuestos organicos. | |
| MX2021013564A (es) | Gamma-carbolinas fusionadas con heterociclo deuterado. | |
| MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
| MX365969B (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
| MX2016013046A (es) | Compuestos organicos. | |
| MX2020000968A (es) | Compuestos organicos. | |
| MX2020000967A (es) | Compuestos organicos. | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| MX2020009929A (es) | Compuestos organicos. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| MX2021007217A (es) | Compuesto organico. | |
| IN2015DN03921A (forum.php) | ||
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| UA118562C2 (uk) | Модулятори рецептора cxcr7 | |
| MY189372A (en) | Indole derivatives | |
| TN2016000557A1 (en) | Pharmaceutical dosage forms | |
| GR1008169B (el) | Φαρμακευτικο σκευασμα περιεχον εναν αντιβακτηριακο παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου | |
| GB2569616B (en) | Sustained release oral pharmaceutical compositions of dicycloverine | |
| HK1220615A1 (zh) | 有机化合物 | |
| IN2013MU03838A (forum.php) | ||
| GR1008082B (el) | Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου | |
| IN2013MU01239A (forum.php) | ||
| IN2013MU01944A (forum.php) |